POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced that the Universal Registration Document for the year ended December 31, 2021 has been filed with the French market authority.